Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24482222)

1.

ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity.

Wei J, Chen X, Li Q, Chen J, Khan N, Wang B, Cheng JW, Gordon JR, Li F.

Oncol Rep. 2014 Apr;31(4):1599-604. doi: 10.3892/or.2014.2996. Epub 2014 Jan 24.

PMID:
24482222
2.

CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.

Khan MN, Wang B, Wei J, Zhang Y, Li Q, Luan X, Cheng JW, Gordon JR, Li F, Liu H.

Oncotarget. 2015 Jun 10. [Epub ahead of print]

3.

Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.

Solanki MH, Chatterjee PK, Xue X, Gupta M, Rosales I, Yeboah MM, Kohn N, Metz CN.

Am J Physiol Renal Physiol. 2015 Jul 1;309(1):F35-47. doi: 10.1152/ajprenal.00096.2015. Epub 2015 May 6.

PMID:
25947343
4.

CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice.

Schneberger D, Gordon JR, DeVasure JM, Boten JA, Heires AJ, Romberger DJ, Wyatt TA.

Pulm Pharmacol Ther. 2015 Apr;31:55-62. doi: 10.1016/j.pupt.2015.02.002. Epub 2015 Feb 12.

PMID:
25681618
5.

G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity.

Li L, Khan MN, Li Q, Chen X, Wei J, Wang B, Cheng JW, Gordon JR, Li F.

Oncol Rep. 2015 Feb;33(2):751-7. doi: 10.3892/or.2014.3659. Epub 2014 Dec 8.

PMID:
25504010
6.

N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.

Muldoon LL, Wu YJ, Pagel MA, Neuwelt EA.

J Neurooncol. 2015 Feb;121(3):433-40. doi: 10.1007/s11060-014-1657-1. Epub 2014 Nov 21.

PMID:
25411097
7.

Osteopontin does not mitigate cisplatin ototoxicity or nephrotoxicity in adult mice.

Schmitt NC, Rubel EW.

Otolaryngol Head Neck Surg. 2013 Oct;149(4):614-20. doi: 10.1177/0194599813498218. Epub 2013 Jul 24.

PMID:
23884286
8.

Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.

Wang CF, Wang YQ, Huang FZ, Nie WP, Liu XY, Jiang XZ.

J Int Med Res. 2013 Aug;41(4):964-74. doi: 10.1177/0300060513483401. Epub 2013 Jul 18.

PMID:
23867448
9.

D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice.

Ueki M, Ueno M, Morishita J, Maekawa N.

Tohoku J Exp Med. 2013;229(3):195-201.

10.

Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.

Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.

Int J Mol Med. 2013 Jan;31(1):33-42. doi: 10.3892/ijmm.2012.1171. Epub 2012 Nov 1.

PMID:
23128378
11.

D-allose ameliorates cisplatin-induced nephrotoxicity in mice.

Miyawaki Y, Ueki M, Ueno M, Asaga T, Tokuda M, Shirakami G.

Tohoku J Exp Med. 2012;228(3):215-21.

12.

G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.

Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR.

Tohoku J Exp Med. 2012;228(2):147-56.

13.

Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor.

de Carvalho Maroni L, de Oliveira Silveira AC, Leite EA, Melo MM, de Carvalho Ribeiro AF, Cassali GD, de Souza CM, Souza-Fagundes EM, Caldas IR, Araújo MS, Martins-Filho OA, de Oliveira MC, Teixeira-Carvalho A.

Exp Biol Med (Maywood). 2012 Aug;237(8):973-84. doi: 10.1258/ebm.2012.011432. Epub 2012 Aug 17.

PMID:
22903135
14.

Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times.

Xu YY, Jiang N, Liu TS, Qu HQ, Wang T.

Mol Med Rep. 2012 Nov;6(5):1075-80. doi: 10.3892/mmr.2012.1033. Epub 2012 Aug 13.

PMID:
22895541
15.

Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: in vivo and cDNA microarray studies.

Yao XQ, Zhang YH, Long W, Liu PX.

Chin J Integr Med. 2012 Mar;18(3):209-13. doi: 10.1007/s11655-012-1001-6. Epub 2012 Apr 2.

PMID:
22466946
16.

Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.

Lavolé A, Danel S, Baudrin L, Gounant V, Ruppert AM, Epaud C, Belmont L, Rosencher L, Cadranel J, Milleron B.

Bull Cancer. 2012 Apr 1;99(4):E43-8. doi: 10.1684/bdc.2012.1555.

PMID:
22450449
17.

Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.

Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG.

Cytokine. 2011 Dec;56(3):616-20. doi: 10.1016/j.cyto.2011.08.034. Epub 2011 Sep 21.

PMID:
21940178
18.

Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity.

Sahu BD, Rentam KK, Putcha UK, Kuncha M, Vegi GM, Sistla R.

Food Chem Toxicol. 2011 Dec;49(12):3090-7. doi: 10.1016/j.fct.2011.08.018. Epub 2011 Sep 6.

PMID:
21930180
19.

Tim-1 promotes cisplatin nephrotoxicity.

Nozaki Y, Nikolic-Paterson DJ, Yagita H, Akiba H, Holdsworth SR, Kitching AR.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1098-104. doi: 10.1152/ajprenal.00193.2011. Epub 2011 Aug 10.

20.

Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO, Dong Z.

J Clin Invest. 2011 Jul;121(7):2709-22. doi: 10.1172/JCI45586.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk